Quarterly Financial Information (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2015

Quarterly Financial Information (Unaudited)

Summary of quarterly financial information

        Summarized quarterly financial information for each of the years ended December 31, 2015 and 2014 are as follows (in thousands, except per share amounts):

	Quarter Ended
	December 31, 2015		September 30, 2015		June 30, 2015		March 31, 2015
Total revenues	$	404,875	$	386,221	$	347,161	$	327,504
Cost of product sales		25,309		6,891		16,058		20,778
Gross profit		379,566		379,330		331,103		306,726
Net income (loss)(1)(2)		104,644		464,425		99,211		(16,641	)
Net income (loss) per share—basic	$	2.29	$	10.20	$	2.15	$	(0.36	)
Net income (loss) per share—diluted	$	2.10	$	9.24	$	1.91	$	(0.36	)

	Quarter Ended
	December 31, 2014		September 30, 2014			June 30, 2014		March 31, 2014
Total revenues	$	346,363	$	329,950		$	322,802	$	289,403
Cost of product sales		15,770		40,804			38,709		30,600
Gross profit		330,593		289,147			284,093		258,803
Net income (loss)(3)		115,935		(25,237	)		111,852		137,524
Net income (loss) per share—basic	$	2.44	$	(0.53	)	$	2.35	$	2.73
Net income (loss) per share—diluted	$	2.17	$	(0.53	)	$	2.10	$	2.43

(1)	Operating results for the quarter ended December 31, 2015, September 30, 2015, June 30, 2015 and March 31, 2015 include $71.6 million, $(75.7) million, $27.5 million and $145.7 million net of tax expense (benefit) to operating expenses for STAP related share-based compensation expense, respectively.
(2)	Operating results for the quarter ended September 30, 2015, include a gain on sale of the PPRV we received from the FDA in connection with the approval of Unituxin, for $350.0 million in cash. The proceeds from the sale of the PPRV were recognized as a gain on the sale of an intangible asset, as the PPRV did not have a carrying value on our consolidated balance sheet at the time of sale.
(3)	Operating results for the quarter ended December 31, 2014, September 30, 2014, June 30, 2014, and March 31, 2014 include $19.9 million, $122.1 million, $(1.4) million and $(39.6) million net of tax expense (benefit) to operating expenses for STAP related share-based compensation expense, respectively.